Admire Dental Butler: Dentist In Butler Launches New Website Under New Management

11 months ago

Butler, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- Admire Dental Butler, a dental clinic that provides a range of oral…

South Perth Dental Surgery: Dentist In South Perth Announces New Customised Dental Implant Solutions

11 months ago

South Perth, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- Founded in 1991, South Perth Dental Surgery is an established Dentist South…

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

11 months ago

MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines…

Better Choice Appoints Kent Cunningham as Chief Executive Officer

11 months ago

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet…

Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-Godefroy

11 months ago

An In-Depth Look at Anti-Aging Compound TFC-1326VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM)…

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

11 months ago

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no…

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

11 months ago

Pivotal top-line data readout expected in mid-2023WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon”…

Venus Concept Announces 1-for-15 Reverse Stock Split

11 months ago

TORONTO, May 11, 2023 (GLOBE NEWSWIRE) --  Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical…

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

11 months ago

– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel…

Orion Corporation: Managers’ transactions – Mikael Silvennoinen

11 months ago

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MAY 2023 at 15.30 EEST          Orion Corporation: Managers’ transactions – Mikael Silvennoinen Orion Corporation…